pancreatic cancer

[Cell Death & Disease] Treatment of PDAC cells with AdipoRon led to mitochondrial uncoupling and loss of ATP production. Concomitantly, AdipoRon-treated cells increased glucose uptake and utilization.

[Cell Death & Disease] Niclosamide inhibited proliferation of pancreatic cancer cells, induced apoptosis via the mitochondrial-mediated pathway, and suppressed cell migration and invasion by antagonizing epithelial-to-mesenchymal transition.

[Molecular Therapy-Oncolytics] The authors provide an overview of current and on-going chimeric antigen receptor (CAR) T cell clinical studies in pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy.

[Karmanos Cancer Institute] The Barbara Ann Karmanos Cancer Institute recently received a $352,437 grant from the U CAN-CER VIVE Foundation to help fund a pancreatic cancer research study.

[Panbela Therapeutics, Inc.] Panbela Therapeutics, Inc. announced the initiation of the company’s global Phase II clinical trial of SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial.

[Oncogene] Scientists performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC (KC mice that harbor K-RAS mutation in pancreatic tissue), where we noted marked upregulation of gastrokine (GKN) proteins.